A phase I study of bevacizumab and amrubicin after platinum-based chemotherapy in patients with advanved non-squamous non-small cell lung cancer
- Conditions
- on-Small Cell Lung Cancer Non-Squamous cell lung cancer
- Registration Number
- JPRN-UMIN000008182
- Lead Sponsor
- ational Hospital Organization Kyushu Medical Center Department of Respiratory Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Not provided
1)Squamous cell carcinoma 2)Discontinued bevacizumab due to its toxicity during a first line treatment 3)Serious infections/with fever 4)Serious clinical problems 5)Interstitial pneumonia/lung fibrosis on chest X-ray 6)History or complication of hemoptysis with 2.5ml per time or more 7)Continuous bloody phlegm more than 1 week or complication of bloody phlegm treated with continuous oral hemostatic agent. History or complication of bloody phlegm treated with infusional hemostatic agent. 8)Tumor cavitation 9)Uncontrollable hypertension 10)History of GI perforation 11)Previous treatment with amrubicin 12)Massive pericardial, pleural effusion, ascites 13)Active concomitant malignancy 14)Symptomatic brain metastasis 15)Previous drug allergy 16)Those judged to be not suitable by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Maximum tolerated dose (MTD) of amrubicin and bevacizumab
- Secondary Outcome Measures
Name Time Method Anti tumor efficacy